NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

US biotech Nektar Therapeutics experienced a remarkable 130% increase in its share price, which reached $21.9, as it reported ...

Enphase Energy a company exhibitor seen at the Bepositive Energy ... More Transition Show. (Photo by Romain Doucelin/SOPA ...

The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients ...

Shares of Nektar Therapeutics (NKTR) more than doubled on Tuesday afternoon after the company announced that its mid-stage ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...

The European Union plans to impose retaliatory tariffs on US imports, including on Boeing Co. aircraft, if President Donald ...

In a busy day for the US drugmaker, Kymera Therapeutics yesterday announced a licensing deal with Gilead Sciences updated on its collaboration with French pharma major Sanofi.